Stock Analiz

Invivyd, Inc. IVVD

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2021 · data as of November 13, 2026

$0.58Market cap $172M
Open the interactive analysis →

Invivyd, Inc. (IVVD) is a healthcare company listed in the US with a market value of about $172M. In the twelve months to June 30, 2026 it had revenue of $58M and net income of -$107M, a net margin of -183.9%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -80%.

About Invivyd

Invivyd is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2021. It was profitable in 0 of the last 5 years in our data. Its share count rose by 59% over three years (dilution for shareholders). It spends 72% of revenue on research and development.

Score: 1.0 / 5

Value0/5
Future growth3/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S2.9
P/B0.9
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-63.9%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)110.5%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-383.8%
ROIC (5-yr avg.)-80.1%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 5 years

Fiscal yearTTM20252024202320222021
Revenue$58M$53M$25M$0——
Net income-$107M-$52M-$170M-$199M-$241M-$227M
Free cash flow-$110M-$58M-$171M-$174M-$222M-$185M
EPS (diluted)$-0.33$-0.30$-1.43$-1.81$-2.23$-5.32
Net margin-183.9%-98.2%-669.4%———
ROIC—-18.1%-201.7%-93.8%-54.9%-32.1%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Invivyd pay a dividend?

Not currently.

Is Invivyd a good stock to buy?

We do not give buy or sell advice. Invivyd scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.